BMC endocrine disorders · 2022
Association between type 2 diabetes status and prevalence of liver steatosis and fibrosis among adults aged ≥ 40 years.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Jun, Hu Piao, Wang Yanfei, Zhu Zhongxin
Аннотация
BACKGROUND: Type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease frequently coexist and share pathophysiological manifestations. This study aimed to explore the association between T2DM status and prevalence of liver steatosis and fibrosis, identified using the controlled attenuation parameter and liver stiffness measurement attained via liver ultrasound transient elastography.
METHODS: This was a cross-sectional analysis of data collected in the National Health and Nutrition Examination Survey for 2017-2018. Multivariable logistic regression model was used to evaluate the association between T2DM and prevalence of liver steatosis and fibrosis. Subgroup analyses, stratified by sex age, race, and body mass index (BMI), were further performed.
RESULTS: Of the 2,780 participants aged ≥ 40 years enrolled, 749 had T2DM, and 2,031 did not. After adjustment for potential confounders, T2DM was associated with a higher prevalence of liver steatosis (OR = 1.7, 95% CI, 1.3-2.1). This T2DM-related prevalence was higher among women (OR = 1.8, 95% CI, 1.3-2.5) and in the non-Hispanic Black (OR = 1.8, 95% CI, 1.1-3.0), other race (OR = 1.9, 95% CI, 1.2-3.0), and BMI < 25 kg/m2 (OR = 2.0, 95% CI, 1.1-3.8) groups. T2DM was also associated with a significantly higher prevalence of fibrosis (OR = 2.0, 95% CI, 1.5-2.7), with this association being more prominent for the other race (OR = 2.9, 95% CI, 1.5-5.5) and BMI < 25 kg/m2 (OR = 3.3, 95% CI: 1.3-8.8) groups.
CONCLUSIONS: Our findings indicated a positive association between T2DM status and prevalence of hepatic steatosis and fibrosis. This association was more prominent for individuals with a BMI < 25 kg/m2 and was influenced by race-specific effects.
METHODS: This was a cross-sectional analysis of data collected in the National Health and Nutrition Examination Survey for 2017-2018. Multivariable logistic regression model was used to evaluate the association between T2DM and prevalence of liver steatosis and fibrosis. Subgroup analyses, stratified by sex age, race, and body mass index (BMI), were further performed.
RESULTS: Of the 2,780 participants aged ≥ 40 years enrolled, 749 had T2DM, and 2,031 did not. After adjustment for potential confounders, T2DM was associated with a higher prevalence of liver steatosis (OR = 1.7, 95% CI, 1.3-2.1). This T2DM-related prevalence was higher among women (OR = 1.8, 95% CI, 1.3-2.5) and in the non-Hispanic Black (OR = 1.8, 95% CI, 1.1-3.0), other race (OR = 1.9, 95% CI, 1.2-3.0), and BMI < 25 kg/m2 (OR = 2.0, 95% CI, 1.1-3.8) groups. T2DM was also associated with a significantly higher prevalence of fibrosis (OR = 2.0, 95% CI, 1.5-2.7), with this association being more prominent for the other race (OR = 2.9, 95% CI, 1.5-5.5) and BMI < 25 kg/m2 (OR = 3.3, 95% CI: 1.3-8.8) groups.
CONCLUSIONS: Our findings indicated a positive association between T2DM status and prevalence of hepatic steatosis and fibrosis. This association was more prominent for individuals with a BMI < 25 kg/m2 and was influenced by race-specific effects.